Targeted antagonism of CXCR4 mobilizes progenitor cells under investigation for cardiovascular disease
- 1 January 2009
- journal article
- clinical trial
- Published by Elsevier in Cytotherapy
- Vol. 11 (8) , 1016-1019
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Angiogenic cells can be rapidly mobilized and efficiently harvested from the blood following treatment with AMD3100Blood, 2006
- Effects of GM-CSF on the stem cells mobilization and plasma C-reactive protein levels in patients with acute myocardial infarctionInternational Journal of Cardiology, 2006
- Outcomes and Risks of Granulocyte Colony-Stimulating Factor in Patients With Coronary Artery DiseaseJACC, 2005
- Proteomic signature of myeloproliferation and neutrophilia: analysis of serum and plasma from healthy subjects given granulocyte colony-stimulating factorExperimental Hematology, 2005
- Granulocyte Colony-Stimulating Factor Mobilizes Functional Endothelial Progenitor Cells in Patients With Coronary Artery DiseaseArteriosclerosis, Thrombosis, and Vascular Biology, 2005
- Inflammatory Markers and the Risk of Coronary Heart Disease in Men and WomenNew England Journal of Medicine, 2004
- Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonistBlood, 2003
- Inflammation in atherosclerosisNature, 2002
- AMD3100, a CxCR4 Antagonist, Attenuates Allergic Lung Inflammation and Airway HyperreactivityThe American Journal of Pathology, 2002
- Vascular complications in patients treated with granulocyte colony-stimulating factor (G-CSF)European Journal of Cancer, 1993